For example, R‐Hyper‐CVAD vs. R‐CHO(E)P showed 5‐year PFS 69% vs. 40% in aaIPI 3, 72% vs. 42% in IPI 4–5, 88% vs. 38% in CNS involvement and 66% vs. 7% in CD5+ lymphoma. The gene discussed is CD5; the disease is lymphoma.